Defence Therapeutics (TSE:DTC)
:DTC
Want to see TSE:DTC full AI Analyst Report?
Top Page
Defence Therapeutics
(DTC)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.52
▼(-33.85% Downside)
Action:Reiterated
Date:05/26/26
The score is driven primarily by weak financial performance (no revenue, recurring losses, and continued cash burn that increases financing/dilution risk). Technicals also pressure the score due to price trading below all key moving averages with negative MACD. Valuation contributes negatively because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Proprietary Platform
The Accum® platform targets intracellular delivery and potency enhancement for biologics across oncology and infectious disease. A platform-style asset can generate multiple pipeline candidates, support partnerships or licensing, and create durable differentiation versus single-product developers.
Negative Factors
No Revenue
Being pre-revenue means the company cannot self-fund operations and remains entirely dependent on external capital. This structural state increases execution risk until a clinical or commercial milestone proves the technology can generate sales and cover development costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Platform
The Accum® platform targets intracellular delivery and potency enhancement for biologics across oncology and infectious disease. A platform-style asset can generate multiple pipeline candidates, support partnerships or licensing, and create durable differentiation versus single-product developers.
Read all positive factors
Defence Therapeutics (DTC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$37.14M
Dividend YieldN/A
Average Volume (3M)68.27K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue GrowthN/A
EPS Growth-40.15%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,788,155
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Defence Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its...
How the Company Makes Money
null...
Defence Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Jun 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -54.15K | -72.34K | -90.92K | -13.82K | 0.00 | 0.00 |
| EBITDA | -4.53M | -3.13M | -12.68M | -6.48M | 0.00 | 0.00 |
| Net Income | -6.34M | -3.52M | -13.19M | -6.76M | -7.34M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 9.45M | 1.65M | 477.75K | 3.53M | 719.67K | 5.61M |
| Cash, Cash Equivalents and Short-Term Investments | 2.95M | 1.23M | 56.55K | 2.79M | 506.70K | 5.45M |
| Total Debt | 1.56M | 1.50M | 1.75M | 1.75M | 0.00 | 0.00 |
| Total Liabilities | 4.03M | 2.91M | 4.06M | 1.97M | 1.11M | 122.26K |
| Stockholders Equity | 5.41M | -1.26M | -3.58M | 1.57M | -387.56K | 5.49M |
Cash Flow | ||||||
| Free Cash Flow | -3.73M | -3.40M | -4.49M | -7.72M | -6.04M | -2.29M |
| Operating Cash Flow | -4.53M | -3.40M | -4.29M | -7.66M | -6.04M | -2.29M |
| Investing Cash Flow | -30.05K | 3.60K | -203.24K | -65.80K | 0.00 | 0.00 |
| Financing Cash Flow | 5.44M | 4.57M | 1.76M | 10.01M | 1.10M | 5.88M |
Defence Therapeutics Technical Analysis
Positive
0.78
Price Trends
0.52
Positive
0.56
Negative
0.66
Negative
Market Momentum
>-0.01
Positive
53.10
Neutral
33.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DTC, the sentiment is Positive. The current price of 0.78 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.52, and above the 200-day MA of 0.66, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 53.10 is Neutral, neither overbought nor oversold. The STOCH value of 33.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DTC.
Defence Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$5.41M | -0.16 | 123.88% | ― | ― | 60.66% | |
44 Neutral | C$37.06M | -0.25 | -221.75% | ― | ― | 85.31% | |
42 Neutral | C$28.53M | -2.67 | -103.51% | ― | ― | 57.98% | |
41 Neutral | C$37.14M | -4.39 | ― | ― | ― | -40.15% | |
| ― | C$2.04M | -0.59 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:DTC
Defence Therapeutics
0.49
-0.24
-32.88%
TSE:APS
Aptose Biosciences
2.12
0.88
70.97%
TSE:MDNA
Medicenna Therapeutics Corp
0.42
-0.46
-52.30%
TSE:BCT
BriaCell Therapeutics
4.26
-35.44
-89.27%
TSE:BIOV
BioVaxys Technology
0.07
-0.33
-82.46%
TSE:ONCO
Onco-Innovations Ltd.
1.47
0.00
0.00%
Defence Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Defence Therapeutics Eases Terms on 800,000 Warrants to Boost Investor Uptake
Positive
Mar 21, 2026
Defence Therapeutics has amended the terms of 800,000 common share purchase warrants originally issued in a 2024 private placement, extending their expiry dates by 12 months and reducing the exercise price from $1.00 to $0.75 per share. None of th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.